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Dr Robert H. Jones (Durham, NC). I thank the association for
the invitation to begin this discussion, and I have nothing to dis-
close other than I am the principal investigator of the National
Institutes of Health–funded STICH trial.
Dr Dor contributed to the initial planning of the STICH trial,
insisted that the operation should be called ventricular recon-
struction and not the Dor operation or restoration operation,
and welcomed STICH surgeons into his institution for training.
Today he described 274 patients with ventricular reconstruction
treated concurrently with STICH enrollment and analyzed their
outcomes by who was and was not STICH eligible. Fifty-seven
percent of his patients were STICH eligible. STICH was de-
signed as a broadly inclusive trial. Enrolled patients were those
that responsible investigators and cardiac surgeons at each insti-
tution considered eligible based on their entire clinical picture.
Therefore the combined zone of uncertain benefit about ventric-
ular reconstruction in the minds of all participating cardiologists
and cardiac surgeons largely determined the characteristics of the
1,000 patients randomized. Because STICH was based on clini-
cal judgment for inclusion, specific exclusions were needed toery c April 2011
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could be generalized to a large and well-defined future popula-
tion. For example, the protocol encouraged enrollment of pa-
tients with ongoing Canadian Cardiovascular Society class 3 or
4 angina undergoing intensive medical therapy but did prohibit
enrollment of patients in cardiogenic shock on maximal support.
The shock was not intended to suggest that patients with cardiac
shock would not benefit from ventricular reconstruction surgery;
it was needed for the integrity of the trial. It was considered un-
likely that insufficient numbers of patients with cardiac shock
would be enrolled to make a definitive subgroup conclusion
about their benefit from ventricular surgery. However, should
this high-risk population experience excess deaths in the ventric-
ular reconstruction randomized treatment arm by statistical
chance, these few patients might be contributing enough deaths
to detract statistical power from the primary conclusion in the
broad population of patients more commonly encountered in rou-
tine clinical practice.
However, this STICH protocol exclusion of ischemic shock need
not prohibit use of the neutral results of the STICH trial for manage-
ment decisions for patients with ICMs. For example, in a patient
with cardiac shock, good coronary arteries for revascularization,
and only mild anterior dyskinesia on cardiac catheterization, one
might decide not to obtain a cardiac magnetic resonance (CMR) im-
age to evaluate the need for adding ventricular reconstruction but
would simply consider the ventriculogram and the echocardio-
graphic findings adequate to simply revascularize that patient.
The STICH trial should not be considered as only informing the
question of whether ventricular reconstruction should or should
not be added to CABG for all patients with ICMs. The broader
question the STICH trial informs is how much extra benefit might
accrue from adding ventricular reconstruction to a specific patient
who otherwise might be treated with CABG only.
Dr Dor, you have known the primary outcome of the STICH
trial for more than a year. Most of the patients with ischemic HF
you reported today could have been entered into the STICH trial.
Has this neutral STICH result changed your equipoise for any of
your health care diagnostic or treatment decisions for ‘‘STICH-
like’’ patients, irrespective of whether they were technically
STICH protocol eligible?
Dr Dor. Thank you. First of all, I want to thank you and to con-
firm that your trial, the STICH trial, was a biased trial because
nearly one half of the patients in the IFV condition after infarction
are excluded to not pollute the results of your trial. You confirmed
this fact, and that is very important because I cannot understand
why the scar was not assessed. In your trial there is not one indi-
cation about the size of the scar, its location, or its percentage,
and in the other paper, it was never precise whether the ventricle
was scarred. I agree totally that if a patient is totally ischemic
with grade 4 Canadian Cardiovascular Association ischemia,
you have to revascularize him or her. Nobody discussed the situa-
tion of when a patient has no more ischemia, a totally destroyed
ventricle, and a large scar involving more than 50% of the ventri-
cle: How can CABG alone improve this patient? That is clinically
very ridiculous in a center in which we take care of this patient.
You are out of reality.
The STICH trial is mathematically, for which we have statistics,
irreproachable. It is a fantastic trial. But medically speaking, it isThe Journal of Thoracic and Caunfounded because more than half of the patients were excluded.
You discuss the acute HF. How do you treat a ruptured septum
not excluding the necrosed cavity?
Can you say to a cardiologist: Treat the patient without treating
the cause and its consequence? It is impossible. Therefore the mes-
sage that I want to be received by the community is that when you
have a patient with an IFV, please make a complete and reliable
assessment, and the use, in 2000’sMRI, is mandatory. If the patient
is ischemic, you can revascularize by means of PCI or surgical in-
tervention; it is not a problem and up to you. But if the patient has
a scarred ventricle, rebuild it, but correctly. Because in your trial,
one thing was astonishing, that even if it is only assessed on one
third of 1,000 patients, the decrease in end systolic volume was
something like 16% (from 82 to 68 mL/m2). That is a ridiculous
result for reconstruction. Usually all our patients are below 60
mL/m2, the threshold of prognosis for a patient. I was surprised
by what was published this year at the American College that in
the group of patients with large dilatation, 22% or 23% EF, the in-
crease after surgical intervention was 2 points for revascularization
and 5 points for ventricular reconstruction. What operation was
done? I cannot understand what it is. Is it a new reconstruction
of the ventricle? I showed the results of our whole identical series:
the decrease of ESVI (from preoperative 95 mL/m2 to postopera-
tive 48 mL/m2) reaches 50%.
Therefore you confirmed the fact that you excluded severe pa-
tients to do not pollute your trial, and our presentation confirms
the fact that the STICH trial is not reliable because patients with
a scarred ventricle are not assessed or treated.
Dr Jones. I will respond briefly to permit others to join the dis-
cussion. The STICH trial was not designed to definitively answer
the question of whether ventricular reconstruction should ever be
done in patients with extensive scarring of the left ventricle. Car-
diac surgeons identified patients for whom adding SVR to CABG
would be ethical as long as the LVEF was 0.35 or less and domi-
nant anterior LV dysfunction was present.
We then documented the best available baseline core labora-
tory measurement of global and regional dysfunction and ven-
tricular size reported from the ECHO, SPECT, and CMR core
laboratories without knowledge of the treatment assignment of
the patient. The results to be published soon document a wide
spectrum of ESVI and regional LV function in the 1,000 STICH
patients. Moreover, the change in global LV function from base-
line to 4 months after the operation will be reported based on
the specific operation performed. These will be the first preop-
erative to postoperative LV volume-change data with results re-
ported using data directly quantitated from images by study
readers who could not have known which operation was per-
formed. We also have radionuclide and CMR gadolinium viabil-
ity measurements on a substantial number of these patients that
are likely to provide additional insight about baseline character-
istics of the STICH patients randomized to CABG with or with-
out SVR.
The knowledge the STICH trial contributed about the value of
ventricular reconstruction applies to a broad spectrum of CABG-
eligible patients with ICMs. Clinical outcomes showed no benefit
of ventricular reconstruction throughout the entire range of clin-
ical and cardiac function parameters and were not dependent on
change in volume 4 months after the operation. Becauserdiovascular Surgery c Volume 141, Number 4 915
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strategies were the same for the end points of death, cardiac
hospitalization, and physiological testing, this lack of harm
from ventricular surgery indicates it would be safe to study other
populations for whom a question of benefit for ventricular surgery
added to CABG remains. The STICH trial provides valuable
data that could be used to design future prospective observational
or randomized studies in other ICM patient populations of
interest.916 The Journal of Thoracic and Cardiovascular SurgDr Dor. I will answer very quickly. I thank you to mention the
neutral results of the STICH trial. Your conclusion must add as
a conclusion that all the cases that were not treated by the STICH
study team will be interesting for cardiologists. Second, regarding
the volumes you mentioned, they are assessed by means of
echocardiographic analysis, and again, in 2000’s magnetic reso-
nance is more reliable to assess the volume of the heart before
and after repair.
I thank you for your comments and I thank the association.ery c April 2011
